Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alexion Pharmaceuticals Inc. ALXN

Healthcare Biotechnology
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS... see more

Recent & Breaking News (NDAQ:ALXN)

Levi & Korsinsky, LLP Notifies Shareholders of Alexion Pharmaceuticals, Inc. (ALXN) an Upcoming Claims Deadline in a Class Action Settlement

Accesswire December 14, 2023

Levi & Korsinsky, LLP Notifies Shareholders of Alexion Pharmaceuticals, Inc. (ALXN) an Upcoming Claims Deadline in a Class Action Settlement

Accesswire December 12, 2023

Levi & Korsinsky, LLP Notifies Shareholders of Alexion Pharmaceuticals, Inc. (ALXN) an Upcoming Claims Deadline in a Class Action Settlement

Accesswire December 7, 2023

Levi & Korsinsky, LLP Notifies Shareholders of Alexion Pharmaceuticals, Inc. (ALXN) an Upcoming Claims Deadline in a Class Action Settlement

Accesswire December 5, 2023

Levi & Korsinsky, LLP Notifies Shareholders of Alexion Pharmaceuticals, Inc. (ALXN) an Upcoming Claims Deadline in a Class Action Settlement

Accesswire November 29, 2023

Levi & Korsinsky, LLP Notifies Shareholders of Alexion Pharmaceuticals, Inc. (ALXN) an Upcoming Claims Deadline in a Class Action Settlement

Accesswire November 14, 2023

ALEXION INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alexion Pharmaceuticals, Inc. - (ALXN)

PR Newswire October 6, 2017

ALEXION INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alexion Pharmaceuticals, Inc. – (ALXN)

Business Wire September 29, 2017

Biotech Investors, Here's Your PDUFA Primer For October

Benzinga.com  September 28, 2017

Robbins Arroyo LLP: Alexion Pharmaceuticals, Inc. (ALXN) Misled Shareholders According to a Recently Filed Lawsuit

Business Wire September 26, 2017

Alexion Adds Paul A. Friedman, M.D. to Its Board of Directors

Business Wire September 14, 2017

Interim Analysis from Phase 3 Open-Label Extension Study Shows Sustained Benefits of Soliris® (Eculizumab) Treatment for Patients with Refractory Generalized Myasthenia Gravis

Business Wire September 13, 2017

Alexion Announces Restructuring to Advance Corporate Strategy

Business Wire September 12, 2017

Alexion to Host Call to Discuss Restructuring to Advance Corporate Strategy at 8:30 a.m. on September 12, 2017

Business Wire September 11, 2017

Technical Snapshots for These Biotech Stocks -- Alnylam Pharma, Alexion Pharma, Albany Molecular Research, and BioCryst Pharma

PR Newswire September 8, 2017

Alexion to Present at Upcoming Investor Conferences

Business Wire September 5, 2017

Approbation par la Commission européenne d’une nouvelle indication pour Soliris® (éculizumab) pour le traitement des patients atteints de myasthénie grave (MG) généralisée réfractaire

Business Wire August 21, 2017

Alexion Receives Three New U.S. Patents for Soliris® (eculizumab), Extending Patent Protection Into 2027

Business Wire August 15, 2017

Investor Network: Alexion Pharmaceuticals, Inc. to Host Earnings Call

Accesswire July 27, 2017

20 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  July 27, 2017